With Danaher’s (DHR)
strong leverage to life sciences and diagnostics, and recurring
revenue, the company is in a good place as the economy goes through its
cyclical shifts. Moreover, the company has the luxury to invest for
growth without really compromising its core quality, and the balance
sheet leaves open the possibility for further growth-driving M&A.
The “but” is that the company’s shares are typically richly valued and
today is no exception. Although Danaher’s valuation isn’t so
unreasonably by the elevated standards of life science tool companies,
investors should at least realize they’re paying a premium for Danaher’s
perceived quality and cyclical resilience.
Read more here:
When It Comes To Danaher, 'More Of The Same' Is Usually Pretty Good
No comments:
Post a Comment